Chromosome 2 (2p16) abnormalities in Carney complex tumours

L Matyakhina*, S Pack*, L S Kirschner, E Pak, P Mannan, J Jaikumar, S E Taymans, F Sandrini, J A Carney, C A Stratakis

Carney complex (CNC, OMIM 160980) is an autosomal dominant syndrome characterised by spotty skin pigmentation, cardiac, skin, and breast myxomas, and a variety of endocrine and other tumours. The disease is genetically heterogeneous; two loci have been mapped to chromosomes 17q22-24 (the CNC1 locus) and 2p16 (CNC2). Mutations in the PRKAR1A tumour suppressor gene were recently found in CNC1 mapping kindreds, while the CNC2 and perhaps other genes remain unidentified. Analysis of tumour chromosome rearrangements is a useful tool for uncovering genes with a role in tumorigenesis and/or tumour progression. CGH analysis showed a low level 2p amplification recurrently in four of eight CNC tumours; one tumour showed specific amplification of the 2p16-p23 region only. To define more precisely the 2p amplicon in these and other tumours, we completed the genomic mapping of the CNC2 region, and analysed 46 tumour samples from CNC patients with and without PRKAR1A mutations by fluorescence in situ hybridisation (FISH) using bacterial artificial chromosomes (BAC)-based probes. Consistent cytogenetic changes of the region were detected in 40 (87%) of the samples analysed. Twenty-four samples (60%) showed amplification of the region represented as homogeneously stained regions (HSRs). The size of the amplicon varied from case to case, and frequently from cell to cell in the same tumour. Three tumours (8%) showed both amplification and deletion of the region in their cells. Thirteen tumours (32%) showed deletions only. These molecular cytogenetic changes included the region that is covered by BACs 400-P-14 and S14-O-11 and, in the genetic map, corresponds to an area flanked by polymorphic markers D2S2251 and D2S2292; other BACs on the centromeric and telomeric end of this region were included in varying degrees. We conclude that cytogenetic changes of the 2p16 chromosomal region that harbours the CNC2 locus are frequently observed in tumours from CNC patients, including those with germline, inactivating PRKAR1A mutations. These changes are mostly amplifications of the 2p16 region, that overlap with a previously identified amplicon in sporadic thyroid cancer, and an area often deleted in sporadic adrenal tumours. Both thyroid and adrenal tumours constitute part of CNC indicating that the responsible gene(s) in this area may indeed be involved in both inherited and sporadic endocrine tumour pathogenesis and/or progression.
Gene amplification may be detected at the cytogenetic level either extrachromosomally, as double minute chromosomes (DMs) (small, dot-like chromosome masses that can contain thousands of copies of an oncogene) or intrachromosomally as homogeneously staining regions (HSRs) that are frequently identified by CGH, a technique that allows the detection of large changes thousands of copies of an oncogene (DMs) (small, dot-like chromosome masses that can contain either extrachromosomally, as double minute chromosomes or intrachromosomally, as HSRs) that are frequently identified by CGH, a technique that allows the detection of large changes in the genome.

In the present study, we first examined eight CNC tumours by CGH, a technique that allows the detection of large changes in tumour DNA (table 1). We detected a low level 2p amplification as a recurrent event in four of eight samples; in one tumour the region amplified was specifically 2p16-2p32. To define more precisely the 2p amplicon in these and other tumours, we extended the genomic mapping of the 2p15-21 region, identified new BACs that map to this locus, and used them to perform fluorescence in situ hybridisation (FISH) on samples from tumours from patients with CNC. Frequent changes of the 2p16 region were identified, interestingly in patients with germline PRKARIA mutations, too. Most tumours showed amplification of the area, in the form of HSRs, suggesting that an oncogene may lie at this chromosomal location.

**MATERIALS AND METHODS**

**Subjects and tissues**

We studied 46 tumours from familial (34) and sporadic (12) cases of CNC. The patients and the histology of their tumours are listed in table 2. All subjects gave informed consent for genetic analysis. The first column of the table provides the designated CAR code for each family assigned by the investigators. The second column shows the histological diagnosis of the tumour studied. The third column lists the genetic locus (CNC1 versus CNC2). "Sporadic" indicates a case with no known family history and presumably de novo mutation of the gene responsible for CNC in this subject. The fourth column lists the results of PRKARIA mutation analysis. The fifth column presents the CGH results. PNPNAD: primary pigmented nodular adrenocortical disease.

<table>
<thead>
<tr>
<th>Case</th>
<th>Kindred</th>
<th>Tumour pathological diagnosis</th>
<th>Locus</th>
<th>Mutation of PRKARIA</th>
<th>CGH results</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAR01</td>
<td>Ovarian cyst</td>
<td>CNC1</td>
<td>c.578delGT</td>
<td>2p; 2p16; 9q34; 19q; 19p</td>
<td>5p; 6</td>
</tr>
<tr>
<td>CAR03</td>
<td>Pituitary adenoma</td>
<td>CNC1</td>
<td>c.578delGT</td>
<td>1p; 2p; 4p; 8p; 17; 16p; 12q; 19; 20; 22</td>
<td>20p</td>
</tr>
<tr>
<td>CAR03</td>
<td>PNPNAD</td>
<td>CNC2</td>
<td>_</td>
<td>6q22; 1q; 10p; 9qter</td>
<td>11</td>
</tr>
<tr>
<td>CAR110</td>
<td>Facial myoxoma</td>
<td>CNC1</td>
<td>c.769C&gt;T</td>
<td>2p16-23; 5q (middle)</td>
<td>4cen-pter</td>
</tr>
<tr>
<td>CAR110</td>
<td>Thyroid carcinoma</td>
<td>CNC1</td>
<td>c.769C&gt;T</td>
<td>2p</td>
<td></td>
</tr>
<tr>
<td>CAR503.01</td>
<td>PNPNAD</td>
<td>Sporadic</td>
<td>Exon 25</td>
<td>1pter-p (middle); 16qter-q (middle); 19; 20; 22</td>
<td>4cen-pter</td>
</tr>
<tr>
<td>CAR515.01</td>
<td>PNPNAD</td>
<td>Sporadic</td>
<td>_</td>
<td>9q34</td>
<td></td>
</tr>
<tr>
<td>CAR06</td>
<td>Skin myoxoma</td>
<td>Sporadic</td>
<td>_</td>
<td>2p</td>
<td></td>
</tr>
</tbody>
</table>

The first column of the table provides the designated CAR code for each family assigned by the investigators. The second column shows the histological diagnosis of the tumour studied. The third column lists the genetic locus (CNC1 versus CNC2). "Sporadic" indicates a case with no known family history and presumably de novo mutation of the gene responsible for CNC in this subject. The fourth column lists the results of PRKARIA mutation analysis. The fifth column presents the CGH results. PNPNAD: primary pigmented nodular adrenocortical disease.

**Table 1: CGH abnormalities in CNC tumours**

<table>
<thead>
<tr>
<th>Case</th>
<th>Kindred</th>
<th>Tumour pathological diagnosis</th>
<th>Locus</th>
<th>Mutation of PRKARIA</th>
<th>CGH results</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAR01</td>
<td>Ovarian cyst</td>
<td>CNC1</td>
<td>c.578delGT</td>
<td>2p; 2p16; 9q34; 19q; 19p</td>
<td>5p; 6</td>
</tr>
<tr>
<td>CAR03</td>
<td>Pituitary adenoma</td>
<td>CNC1</td>
<td>c.578delGT</td>
<td>1p; 2p; 4p; 8p; 17; 16p; 12q; 19; 20; 22</td>
<td>20p</td>
</tr>
<tr>
<td>CAR03</td>
<td>PNPNAD</td>
<td>CNC2</td>
<td>_</td>
<td>6q22; 1q; 10p; 9qter</td>
<td>11</td>
</tr>
<tr>
<td>CAR110</td>
<td>Facial myoxoma</td>
<td>CNC1</td>
<td>c.769C&gt;T</td>
<td>2p16-23; 5q (middle)</td>
<td>4cen-pter</td>
</tr>
<tr>
<td>CAR110</td>
<td>Thyroid carcinoma</td>
<td>CNC1</td>
<td>c.769C&gt;T</td>
<td>2p</td>
<td></td>
</tr>
<tr>
<td>CAR503.01</td>
<td>PNPNAD</td>
<td>Sporadic</td>
<td>Exon 25</td>
<td>1pter-p (middle); 16qter-q (middle); 19; 20; 22</td>
<td>4cen-pter</td>
</tr>
<tr>
<td>CAR515.01</td>
<td>PNPNAD</td>
<td>Sporadic</td>
<td>_</td>
<td>9q34</td>
<td></td>
</tr>
<tr>
<td>CAR06</td>
<td>Skin myoxoma</td>
<td>Sporadic</td>
<td>_</td>
<td>2p</td>
<td></td>
</tr>
</tbody>
</table>

The first column of the table provides the designated CAR code for each family assigned by the investigators. The second column shows the histological diagnosis of the tumour studied. The third column lists the genetic locus (CNC1 versus CNC2). "Sporadic" indicates a case with no known family history and presumably de novo mutation of the gene responsible for CNC in this subject. The fourth column lists the results of PRKARIA mutation analysis. The fifth column presents the CGH results. PNPNAD: primary pigmented nodular adrenocortical disease.

**Table 2: Subjects and tissues**

<table>
<thead>
<tr>
<th>Case</th>
<th>Kindred</th>
<th>Tumour pathological diagnosis</th>
<th>Locus</th>
<th>Mutation of PRKARIA</th>
<th>CGH results</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAR01</td>
<td>Ovarian cyst</td>
<td>CNC1</td>
<td>c.578delGT</td>
<td>2p; 2p16; 9q34; 19q; 19p</td>
<td>5p; 6</td>
</tr>
<tr>
<td>CAR03</td>
<td>Pituitary adenoma</td>
<td>CNC1</td>
<td>c.578delGT</td>
<td>1p; 2p; 4p; 8p; 17; 16p; 12q; 19; 20; 22</td>
<td>20p</td>
</tr>
<tr>
<td>CAR03</td>
<td>PNPNAD</td>
<td>CNC2</td>
<td>_</td>
<td>6q22; 1q; 10p; 9qter</td>
<td>11</td>
</tr>
<tr>
<td>CAR110</td>
<td>Facial myoxoma</td>
<td>CNC1</td>
<td>c.769C&gt;T</td>
<td>2p16-23; 5q (middle)</td>
<td>4cen-pter</td>
</tr>
<tr>
<td>CAR110</td>
<td>Thyroid carcinoma</td>
<td>CNC1</td>
<td>c.769C&gt;T</td>
<td>2p</td>
<td></td>
</tr>
<tr>
<td>CAR503.01</td>
<td>PNPNAD</td>
<td>Sporadic</td>
<td>Exon 25</td>
<td>1pter-p (middle); 16qter-q (middle); 19; 20; 22</td>
<td>4cen-pter</td>
</tr>
<tr>
<td>CAR515.01</td>
<td>PNPNAD</td>
<td>Sporadic</td>
<td>_</td>
<td>9q34</td>
<td></td>
</tr>
<tr>
<td>CAR06</td>
<td>Skin myoxoma</td>
<td>Sporadic</td>
<td>_</td>
<td>2p</td>
<td></td>
</tr>
</tbody>
</table>

The first column of the table provides the designated CAR code for each family assigned by the investigators. The second column shows the histological diagnosis of the tumour studied. The third column lists the genetic locus (CNC1 versus CNC2). "Sporadic" indicates a case with no known family history and presumably de novo mutation of the gene responsible for CNC in this subject. The fourth column lists the results of PRKARIA mutation analysis. The fifth column presents the CGH results. PNPNAD: primary pigmented nodular adrenocortical disease.

**Genomic comparative hybridisation (CGH)**

CGH was performed as described previously. Genomic DNA was extracted from the frozen tissues using the Qiagen kit (Qiagen Inc, Chatsworth, CA). Human reference DNA was extracted from peripheral blood lymphocytes of a normal female donor. Tumour and reference DNA was labelled by biotin-11-dUTP and digoxigenin-11-dUTP (Roche Molecular Biochemicals, Mannheim, Germany), respectively. One µg of each of the labelled probes was hybridised in the presence of excess Cot-1 and herring sperm DNA (Life Technologies, Gaithersburg, MD) to metaphase chromosomes prepared from a healthy subject. The biotin labelled tumour genome was visualised with avidin conjugated to fluorescein isothiocyanate (Vector Laboratories Inc, Burlingame, CA), and the digoxigenin labelled reference DNA was detected with antidigoxigenin rhodamine (Roche Molecular Biochemicals, Mannheim, Germany). Chromosomes were counterstained with DAPI (4', 6'-diamidino-2-phenylindol-dihydrochloride). Digital acquisition of grey scale images of the fluorescein isothiocyanate labelled tumour DNA, the tetra-methylrhodamine isothiocyanate labelled reference DNA, and the DAPI counterstain was done using a cooled charge coupled device camera connected to a Leica microscope equipped with fluorochrome specific optical filters. IP Lab Image software (Scan Analytics Corp, VA) was used for image acquisition. The profiles of the tumour:reference fluorescence intensity ratios were generated using Vysis Quantitative Image Processing System (QUIPS CGH). Average ratio profiles were computed as the mean value of at least eight ratio images to identify chromosomal copy number changes in all cases.

**Genomic mapping of bacterial artificial chromosomes (BACs) on 2p16**

BACs that have been characterised and mapped to the chromosome 2p15-21 region, as well as newly identified clones were used in the experiments. Fig 1 displays these and their location on the 2p16 genomic map, based on the 2p15-21 map that was described elsewhere. The current map consists of over 100 large insert clones and contains over 150 polymorphic and non-polymorphic STS. It covers approximately 10 Mb of physical distance between the markers D2S378 at the centromeric end and D2S391 at the telomeric end. In the process of mapping the work, 41 new STSs were generated and placed on the map (Kirschner and Stratakis, unpublished data).

Briefly, the isolation of new BACs and STS/EST content mapping was done as follows: polymerase chain reaction (PCR) analyses of all DNA samples were carried out under standardised conditions consisting of 10 µl reactions that contained 1 × PCR buffer 1 (Perkin-Elmer, Foster City, CA), 200 µmol/l each dNTP, 0.6 µmol/l of forward and reverse primers, 50 µg DNA, and 0.5 U Taq polymerase. The reaction mixtures also contained 1% sucrose and 180 mmol/l cresol red to facilitate direct loading of the samples after PCR. Cycling reactions were performed with an initial five minute denaturation step at 95°C, followed by 30 cycles of 95°C for one minute, 56°C for one minute, and 72°C for one minute. Primer sets that did not
generate reproducible bands from whole human genomic DNA were not considered for further use. For EST/STS content mapping, BAC DNAs were prepared from 5 ml overnight cultures, using commercially available kits (Puregene, Gentra Biosystems, Minneapolis, MN) and spin miniprep columns (Qiagen Corp, Valencia, CA), respectively.

To obtain BAC end sequences, DNA samples from individual clones were purified using a modified alkaline lysis procedure. DNA purified in this way was sequenced directly with Big-Dye Terminators (Perkin-Elmer, Foster City, CA).

CHEF Mapper II apparatus (Biorad Laboratories, Hercules, CA), using programs recommended by the manufacturer to resolve DNA fragments of the appropriate size.

**Fluorescence in situ hybridisation (FISH)**

FISH was performed as described elsewhere. In brief, DNA was labelled by digoxigenin-11-dUTP or biotin-11-dUTP by nick translation followed by anti-dig-rhodamine or avidin-FITC detection. After precipitation in ethanol in the presence of 50% deionised formamide/10% dextran sulphate/2 × SSC, the DNA pellet was resuspended in Hybrizol solution (50% Cot-1 fraction of human herring sperm DNA and 50 × SSC) and captured on a Photometrics cooled CCD camera.

The first column of the table gives the assigned CAR code. The second column provides the histological diagnosis of the tumour studied, if a cell line was studied this is indicated in parentheses (CL). The third column provides the genetic locus information (CNC1 versus CNC2). "Sporadic" indicates a case with no known family history, as above. The fourth column shows the results of PRKAR1A mutation analysis. The fifth column presents the results of the study. Amplification, Del=deletion, NA=not analysed, Nl=normal (two signals of BAC analysed), LCCSCT=large cell calcifying Sertoli cell tumour, PPNAD=primary pigmented nodular adrenocortical disease.
more than 90% of the cells. Hybridisation to tumour cells and showed two expected signals in control probes from other chromosomes (see below) were also used for chromosome identification. Normal tissues from patients showed less than 8% of cells with only one BAC signal varying insignificantly between samples. For all analyses, \( \chi^2 \) test with Fisher’s correction, when appropriate, was performed using the Statistica software (StatSoft, Tulsa, OK).

RESULTS

CGH

We performed CGH on eight samples of tumours from CNC patients, as a first screening technique to detect possible large scale chromosomal aberrations associated with these lesions. These results are presented in table 1.

The most frequent changes were gains, whereas losses were detected in only five of eight samples. The greatest number of changes were detected in cases 1, 2 and 6 (ovarian cyst, pituitary adenoma, and PPNAD). Three samples (cases 5, 7, and 8) with BAC 400-P-14 and its most proximal BAC 514-O-11; characteristic distance, far above and below the borders of the 2p15-21 region, respectively. This region of amplification included therefore more than 10 Mb of genomic DNA was extracted as described elsewhere. A chromosome 2 specific centromeric \( \alpha \)-satellite probe (Vysis) or a painting probe specific for chromosome 2 were also used for chromosome identification.

Statistical analysis

For all analyses, \( \chi^2 \) test with Fisher’s correction, when appropriate, was performed using the Statistica software (StatSoft, Tulsa, OK).

Identification of new BACs

A total of 12 new BACs, identified by STS to map to the previously described 2p15-21 contig, are presented in fig 2. They complement the existing map, but leave unclosed the known central gap. Their location was confirmed by fiber-FISH (data not shown) and was correlated with known BACs.

Amplification of the 2p16-21 region

In order to define more precisely the region amplified on 2p, we used FISH with BACs from the 2p15-p21 region. Table 2 presents results of FISH on 46 tumour samples. Abnormalities were detected in the 34 tumours studied but only in six of the 12 cell lines; the difference was statistically significant (p<0.05). FISH detected amplification of the region in 24 (60%) of 40 tumours that showed abnormalities (fig 3C-F). Three tumours (8%) showed both amplification and deletion of the region in their cells. To define the extent of the region of amplification, we used dual colour FISH with BAC probes from the centromeric and telomeric borders of 2p16-21. BACs 338-A-14 and 18-A-5 were not amplified, establishing the extent of the region of amplification in cases 1, 2, and 6 (ovarian cyst, pituitary adenoma, and PPNAD). Three samples (cases 5, 7, and 8) showed no signal, 3% showed one signal, 3% three signals, and 3% four signals. In the analysis of tumour cells, the 2p16 region was classified as amplified if more than 5% of cells contained multiple signals of the probe being tested and two copies of chromosome 2. The presence of more than 20% cells with only one BAC signal was interpreted as an allelic deletion. Normal tissues from patients showed less than 8% of cells with one BAC signal varying insignificantly between samples. Control probes from other chromosomes (see below) were also hybridised to tumour cells and showed two expected signals in more than 90% of the cells. For all FISH experiments, control probes from chromosomes 1, 4, 10, 16, and 22 were used. All BACs were obtained from a commercially available library (Research Genetics).
cases 2, 17, and 33); the majority of the specimens showed low or mid-level amplification counting 4-20 copies of the probe. Probes displayed a tandem pattern of amplification in the interphase nuclei indicating the presence of HSRs, which were seen as a side by side duplication of dual colour BAC signals (fig 3C, D). Metaphase FISH analysis of a cell line established from a cheek myxoma (case 34) showed cells with differential signal intensity of the 2p16 region (fig 3E).

The region of most consistent amplification was defined by BAC clones 400-P-14, 435-I-1, and 514-O-11 (D2S2251-D2S2292). These BACs were included in the amplicon of all tumours that displayed amplification. They also had a greater copy number than the BACs used in the present study (fig 2); in one tumour, BACs 400-P-14 and 435-I-1 showed higher level of amplification and in a greater number of cells than BAC 514-O-11, although in all other tumours these three BACs had a similar degree of amplification.

Control experiments for the amplification

FISH analysis with \( \alpha \)-satellite probe specific for chromosome 2 centromere detected two copies of the chromosome in all tumours analysed indicating that the cells were diploid. In addition, the 2p16 BACs that showed copy number gain on CNC tumours were hybridised to normal tissues from the same patients; the expected two copies were found in all cells. BAC clones from chromosomes 1, 10, 16, and 22 when hybridised to CNC tumours also showed the expected two signals. Additionally, control experiments included hybridisation of BACs 400-P-14 and 514-O-11 to prostate adenoma tumour cells (fig 4D), breast cancer cell lines HTB22 and HTB30, and pancreatic cancer cell line CRL1240. Two signals of equal intensity were shown in more than 90% of prostate adenoma cells examined. Breast cancer cell lines HTB22 and HTB30 showed equal copy numbers of the BACs and \( \alpha \)-satellite probe specific for chromosome 2 centromeres. Pancreatic cancer cells also showed no amplification of BACs 400-P-14 and 514-O-11, although we detected a translocation of the region (data not shown). Taken together, the data allowed us to conclude that the cytogenetic changes of the 2p16 region were specific to CNC.

Deletion of 2p16 region

In addition to amplification of the 2p16-21 region in CNC tumours, we also detected an allelic deletion of the region in 13 tumours (32%); amplification and deletion were seen in three tumours (table 2). Some tumours, primarily those of adrenocortical origin, lost the whole chromosome 2 as shown by FISH experiments with a chromosome 2 specific centromeric \( \alpha \)-satellite probe or a chromosome 2 specific painting.
probe. However, most of the samples showed two copies of chromosome 2 in their cells.

The size of the deleted region in these tumours varied, but it was generally considerably smaller than the region of amplification. It was flanked by BACs 325-M-13 (2p16.3) and 400-P-14 (2p16.1) from the telomeric and centromeric sides, respectively (fig 1). Dual colour FISH with BACs from within the region narrowed the boundaries of the deleted region. For example, FISH of BACs 400-P-14 and 422-A-6 (fig 4B) or 400-P-14 and 542-M-2 to PPNADs from cases 10 and 36, respectively, showed a deletion only of BAC 400-P-14, whereas BACs 422-A-6 and 542-M-2 were present in two copies. FISH with BACs 400-P-14 and 406-J-5 showed a deletion of BAC 400-P-14, but BAC 406-J-5 showed two signals in cases 10 and 29 (fig 4F). FISH of BACs 400-P-14 and 514-O-11 (fig 4C) to skin myxoma cells (case 12) showed a deletion of both BACs establishing the minimal size of the deleted region in CNC tumours (fig 2).

BAC 435-I-1 that was the nearest one to BAC 400-P-14 (and slightly overlaps with it) on the physical map of the 2p16 region was lost in CNC tumours together with BAC 400-P-14. BAC 112-l-8 that maps more centromeric to BAC-400-P-14 showed two signals in all tumours analysed. Taken together, these data suggested that the region covered by BACs 400-P-14, 435-I-1, and BAC 514-O-11 most probably contained the CNC2 locus. Based on the sizes of BACs 400-P-14, 435-I-1, and 514-O-11 (160, 125, and 160 kb, respectively) and taking into account the overlapping of BACs 400-P-14 and 435-I-1 on the published map, we can assume that the size of this region is approximately 400-450 kb.

Control experiments for the deletions
Prostate adenoma tumours used as controls showed less than 10% of cells with one signal of BACs 400-P-14 or 514-O-11. FISH with other 2p16 BACs also showed the expected two signals. Breast cancer cell lines HTB22 and HTB30 showed equal copy numbers of these BACs and α-satellite probes that are...
specific for the centromere of chromosome 2. When possible, normal tissue associated with the CNC tumours was also hybridised with the corresponding BAC; no abnormalities were detected in these cells. Finally, control experiments included hybridisation of BAC clones from chromosomes 1, 4, 16, and 22 to CNC tumours. The expected two signals were detected in more than 90% of cells, suggesting that the observed 2p16 changes were probably specific for CNC tumours.

**DISCUSSION**

In this study, CGH showed a low level amplification of 2p as the most consistent abnormality in CNC tumours. One tumour showed amplification of 2p16-23 narrowing the region of search. Previous genetic mapping also narrowed the affected region to an approximately 2 Mb long area between markers D2S2153 and D2S1352. Therefore, we examined the region for cytogenetic changes using FISH analysis of CNC tumours with the previously identified, as well as new, BACs from the 2p15-p21 contig.

Overall, more abnormalities were found in touch preparations than in primary cell lines, most likely the result of overgrowth of fibroblasts in cultures. Amplification of the region represented by HSRs occurred in 60% of the samples, deletions in 32%, and amplification and deletion of 2p16 in different cell populations from the same lesion in the remaining 8%. These data are consistent with the CGH data and our previous findings of inconsistent microsatellite alterations of the 2p16 region. There have been no previous reports of consistently amplified or deleted chromosomal regions in CNC tumours.

---

**Figure 4** Deletion of 2p16 region in CNC tumours. (A) FISH with BAC 400-P-14 (red) and α-satellite probe specific for chromosome 2 (green) to fibromyxoma cells (case 12). A metaphase spread and a nucleus, located in the lower left of the image, showed deletion of only the 2p16 region; the centromeric α-satellite probe showed the expected two signals. A third cell was normal, showing two copies of each probe. (B) Interphase FISH to ovarian tumour cells (case 29) with BACs 400-P-14 (red) and 422-A-6 (green) showed deletion of BAC400-P-14; BAC 422-A-6 showed two signals. (C) FISH with BACs 400-P-14 (red) and 514-O-11 (green) to PPNAD cells (case 10) showed deletion of both BACs; these BACs were situated very close to each other on the physical map of 2p16 region. (D) Prostate adenoma cells used as control hybridised with BACs 400-P-14 and 514-O-11 showed two copies of both probes. (E) Ovarian tumour cells (case 41) hybridised with BACs 400-P-14 and 435-I-1 that had the partial overlap with BAC400-P-14 showed deletion of both BACs in four cells; the other three cells were normal, showing two copies of each probe. (F) Hybridisation of BACs 400-P-14 (red) and 406-J-5 (green) to PPNAD cells (case 10). Cells showed deletion of BAC 400-P-14 and two copies of 406-J-5.
tumours as determined by conventional cytogenetic analysis. Chromosome 2 was involved in some of the chromosome rearrangements that were seen in sporadic or associated with CNC myxomas.\(^5\)\(^6\) However, these changes were non-clonal and 2p16 was not specifically investigated.

Dual colour FISH with BACs from opposite sites of the CNC region helped to establish the boundaries of the identified amplicon. Despite the extensive variability from tumour to tumour and even from cell to cell within the same tumour, amplification always included the region covered by BAC400-P-14, 435-I-1, and 514-O-11, although the latter was consistently less amplified than the former two. Interestingly, these BACs were also involved in all tumours that showed deletion of 2p16. Dual colour FISH using BAC 400-P-14 and other BACs in its proximity helped us to estimate the minimal size of the genomic region deleted in a number of CNC tumours. The region was covered by BAC 400-P-14 and overlapped with BAC435-I-1 and BAC514-O-11. Thus, the size of the deleted region was identical to that with the highest level of amplification.

To date, several ESTs from the 2p16 CNC critical region, including five ESTs that represent four different genes from BAC 400-P-14, have been identified and excluded as CNC2 candidates\(^5\)\(^6\) (Kirschner and Stratakis, unpublished data). The 2p21 region has been recently reported to harbour the protein kinase C-epsilon gene (PRKCE) that is amplified in thyroid cancer.\(^5\) We mapped BAC 1D9 containing this gene and found that it was located considerably more telomeric than CNC2 and well above the region of chromosome 2 that was amplified or deleted in all CNC tumours (unpublished data).

The presence of amplification on 2p16-21 suggests the presence of an oncogene that may be responsible for tumorigenesis in CNC patients. The loss of this region in a number of CNC tumours would be similar to losses observed in other tumours caused by abnormal activation of an oncogene, such as MET in carcinomas,\(^5\) and RET in phaeochromocytomas.\(^5\) We speculate that the oncogenic activity of this unidentified gene may be mediated by overexpression of the mutant allele in tumours where amplification is seen, or the exclusive expression of the mutant allele in the absence of the wild type allele in tumours where deletion is seen. Unfortunately, in the cases in which deletion was found, the disease was either sporadic or DNA was not available from affected relatives to test for the inheritance of the mutant versus that of the wild type allele.

Mechanisms that underlie the process of amplification are still not well known; it is generally believed to occur during the late stages of carcinogenesis. However, in our study, when amplification was detected it occurred mostly in benign tumours. This prompted us to look for a feature in the 2p16 region that would make it different from other genomic areas. In fact, 2p16 contains the relatively infrequently expressed, aphidicolin sensitive, fragile site FRA2D. Some models of amplification involve common fragile sites\(^5\) which occur with varying frequencies in the population.\(^5\)\(^7\) Such sites may predispose DNA to the genomic instability observed in cancer.\(^5\) They may or may not affect the function of a gene. An example of this is that of the fragile histidine triad (FHIT), which maps to the FRA3B site on chromosome 3 and is involved in cell cycle regulation; its abnormalities have been associated with a variety of tumours.\(^5\)\(^8\) A different and less frequent fragile site on chromosome 11 has been associated with the common breakpoint identified in chronic lymphocytic leukaemia.\(^5\) The difficulty we encountered in the genomic sequencing of 2p16 and its instability in tumours may be related to the presence of the FRA2D fragile site; characterisation of the latter will shed more light on its relevance to tumorigenesis.

The pattern of cytogenetic changes (amplification or deletion) on 2p16 does not seem to be associated with any clinical or histopathological features of the tumours studied. For example, among 20 PPNAD cases examined in this study, eight showed deletion, nine showed amplification, and two showed both. A remarkable observation is that the changes of the 2p16 region were observed in tumours from CNC patients, with and without PRKAR1A mutations (mapping to 17q and 2p and elsewhere, respectively). We also analysed CNC1 and CNC2 tumours with regard to their type of cytogenetic abnormality (amplification or deletion); 18 of 23 tumours from a total of 28 CNC1 tumours showed amplification and five showed deletion. From 14 of 16 CNC2 tumours, an equal number of tumours (n=7) showed amplification or deletion. This is not a statistically significant difference (p=0.07) but it may represent a trend for 2p16 amplification to be more frequent in CNC1 tumours.

Because the phenotypes of CNC1 and CNC2 patients are not significantly different, it has been suggested that both CNC genes could be involved in the same molecular pathway.\(^5\) This study certainly supports this notion. From our results, the following mechanism of tumorigenesis in CNC1 emerges (fig 5):

**Figure 5** A diagram of potential molecular “hits” in CNC1 tumours; details are provided in the Discussion (see text).
a germline mutation of \textit{PRKARIA} serves as the “first hit”, and LOH of \textit{PRKARIA} as the second hit (although it may not always be necessary), whereas 2p alterations serve as yet another molecular event that may be necessary for tumor formation in this syndrome.

In summary, our results suggest the presence of putative candidate gene(s) on 2p16 that may be responsible for CNC2 and have oncogenic function in at least a subset of families. Our data also imply that cytogenetic alterations in the 2p16 region may be one of the earliest events in the pathogenesis of CNC tumours.

**ACKNOWLEDGEMENTS**

We thank the patients, their families, and physicians who participated in the CNC complex study run by the National Institute of Child Health and Human Development; we also thank the nursing staff of the 8W and 9W wards of the NIH Clinical Centre, our surgeons (Dr R Alexander and Dr S Libutti, NCI, NIH) and our study coordinator, Margaret Keil, RN NPN.

**Authors’ affiliations**

L Matyakhina, L S Kirschner, SE Taymays, F Sandrinini, C A Stratokis, Section on Endocrinology and Genetics, Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA
S Pack, P Morano, J Jaiakumar, Surgical Neurology Branch, National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
E Pak, Cytogenetic and Confoocal Microscopy Core, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA
J A Carney, Mayo Clinic, Rochester, MN 55905, USA
L Matyakhina, Institute of Cytology and Genetics, Russia Academy of Sciences,科学院, Siberian Department, Novosibirsk, Russia

**REFERENCES**

Chromosome 2 (2p16) abnormalities in Carney complex tumours

L Matyakhina, S Pack, L S Kirschner, E Pak, P Mannan, J Jaikumar, S E Taymans, F Sandrini, J A Carney and C A Stratakis

doi: 10.1136/jmg.40.4.268

Updated information and services can be found at:
http://jmg.bmj.com/content/40/4/268

These include:

References
This article cites 48 articles, 13 of which you can access for free at:
http://jmg.bmj.com/content/40/4/268#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
- Endocrine cancer (56)
- Dermatology (240)
- Molecular genetics (1254)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/